CureVac (NASDAQ: CVAC) works on mRNA coronavirus vaccine candidates. If it’s successful, mRNA vaccine giants Modern and Pfizer Competition will come. In this Motley Fool Live Video recorded on June 22ndOlivia Zitkus, editor and analyst for the Health and Cannabis Bureau, and Adria Cimino, editor at Fool.com, discuss whether investors should buy CureVac stock to invest in this breakthrough technology.
Olivia Zitkus: What do you think of that as an mRNA bet? People are talking about Moderna as a bet on mRNA for the rest of their pipeline. What do you think of CureVac? As you mentioned earlier, it’s a lot easier to set up a new vaccine to change the code – I’ll be using that language – and tell the body to produce something different, to maybe a different variant of the coronavirus or a completely different one Virus or other disease. What do you think of this mRNA bet?
Adria Cimino: Well, I think it’s still risky right now because Moderna showed, “Hey, we can do it.” Now let’s apply it to many different areas. CureVac, because of these dates, you have to show us that you can. They need to show better data, in my opinion, before we can say OK. At the moment it might be a bet for very aggressive investors because they think, well, I can get it for a very good price and I’ll take a small position in it while Moderna is up quite a bit. But I would feel a bit more confident investing in Moderna now because they have proven they can, and they have the data behind it and everything. At the moment, CureVac is still quite risky.
This article represents the opinion of the author who may disagree with the “official” referral position of a premium advisory service from the Motley Fool. We are colorful! Questioning an investment thesis – even one of our own – helps us all think critically about investing and make decisions that will help us get smarter, happier, and richer.